how big is Tulasee Bio-Eth.?

As of Jun 03, Tulasee Bio-Ethanol Ltd has a market capitalization of 10.00 Cr, with recent net sales of 0.00 Cr and a net profit of -0.14 Cr. Shareholder's funds are valued at 0.83 Cr, and total assets amount to 8.21 Cr.

Market Cap: As of Jun 03, Tulasee Bio-Ethanol Ltd has a market capitalization of 10.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, which is Standalone data, Tulasee Bio-Ethanol Ltd reported Net Sales of 0.00 Cr and a Net Profit of -0.14 Cr.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of Mar'24. The Shareholder's Funds are valued at 0.83 Cr, and the Total Assets amount to 8.21 Cr.

What does Tulasee Bio-Eth. do?

Tulasee Bio-Ethanol Ltd manufactures absolute alcohol and ethanol, operating as a micro-cap company. It was incorporated in 1988 and reported no net profit for the latest quarter ending March 2025, with a market cap of Rs 10 Cr.

Overview: <BR>Tulasee Bio-Ethanol Ltd is engaged in the manufacturing of absolute alcohol and ethanol, operating within the commodity chemicals industry and classified as a micro-cap company.<BR><BR>History: <BR>The company was incorporated in 1988 under the name Bee-Am & Chemical Limited and was later renamed Tulasee Distilleries Limited. It adopted its current name, Tulasee Bio-Ethanol Limited, on May 8, 2003. The latest quarterly results reported are for March 2025, showing no net profit.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 10 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 10.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 7.32 <BR>Return on Equity: 48.00% <BR>Price to Book: 10.15 <BR><BR>Contact Details: <BR>Address: 41/3&41/5 Village Lohop Chowk, Lohop Road Khalapur Taluk Raigad Maharashtra : 400202 <BR>Tel: 02192-50830 <BR>Email: tulaseebio@gmail.com <BR>Website: http://www.tulaseebio-ethanolltd.com

Who are in the management team of Tulasee Bio-Eth.?

As of March 2022, the management team of Tulasee Bio-Eth includes Kapil Nagpal (Managing Director & CFO), Ashwin G Pandya, Kishor Tank, and Anil Goyal (all Independent Directors), and Kritika Lalitkumar Nagpal (Non-Executive Director). Each member contributes to the company's governance and strategic direction.

As of March 2022, the management team of Tulasee Bio-Eth consists of the following individuals:<BR><BR>1. Kapil Nagpal - Managing Director & CFO<BR>2. Ashwin G Pandya - Independent Director<BR>3. Kishor Tank - Independent Director<BR>4. Anil Goyal - Independent Director<BR>5. Kritika Lalitkumar Nagpal - Non Executive Director<BR><BR>Each member plays a significant role in the governance and strategic direction of the company.

Has Tulasee Bio-Eth. declared dividend?

No Dividend History Available

Who are the peers of the Tulasee Bio-Eth.?

Tulasee Bio-Eth.'s peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Gujarat Alkalies, Kobo Biotech, and Padmanabh Inds., with India Glycols showing the highest growth and return. Management risks vary, with GHCL rated excellent, while Tulasee Bio-Eth. has a 1-year return of -6.77%.

Peers: The peers of Tulasee Bio-Eth. are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Gujarat Alkalies, Kobo Biotech, and Padmanabh Inds.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL, while Good management risk is found at Chemplast Sanmar. Average management risk is present at Tata Chemicals and India Glycols, while Below Average management risk is noted for Fischer Medical and Gujarat Alkalies. Tulasee Bio-Eth., Kobo Biotech, and Padmanabh Inds. do not qualify for management risk assessment. In terms of growth, India Glycols stands out with Above Average growth, while the rest, including Tata Chemicals, Chemplast Sanmar, GHCL, Fischer Medical, Gujarat Alkalies, and the rest, exhibit Below Average growth. All peers except Tulasee Bio-Eth., Kobo Biotech, and Padmanabh Inds. have varying capital structures, with GHCL and Gujarat Alkalies showing Excellent capital structure, while Tata Chemicals and the rest have Average or Below Average ratings.<BR><BR>Return Snapshot: India Glycols has the highest 1-year return at 150.59%, while Kobo Biotech has the lowest at -39.28%. Tulasee Bio-Eth. has a 1-year return of -6.77%, which is significantly better than Kobo Biotech but worse than India Glycols. Additionally, peers such as Gujarat Alkalies and Kobo Biotech have negative six-month returns.

Is Tulasee Bio-Eth. overvalued or undervalued?

As of April 25, 2023, Tulasee Bio-Eth. is considered a risky investment with a low PE ratio of 10.15 and a high ROE of 48.00%, indicating potential undervaluation compared to peers like Solar Industries and Godrej Industries, despite its recent underperformance against the Sensex.

As of 25 April 2023, the valuation grade for Tulasee Bio-Eth. has moved from does not qualify to risky, indicating a shift in perception regarding its investment potential. The company appears to be undervalued, particularly when considering its PE ratio of 10.15 and an impressive ROE of 48.00%, despite a concerning EV to EBIT and EV to EBITDA of -17.47. These ratios suggest that while the company is generating high returns on equity, it is struggling with profitability metrics.<BR><BR>In comparison to its peers, Tulasee Bio-Eth. stands out with a significantly lower PE ratio than Solar Industries India Ltd., which has a PE of 123.77, and Godrej Industries Ltd., which has a PE of 46.63. This stark contrast highlights the potential undervaluation of Tulasee Bio-Eth. relative to its peers, especially given the high valuation levels of the industry. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -3.26% compared to the Sensex's 5.62%, further reinforcing the notion that it may be undervalued in the current market context.

What is the technical trend for Tulasee Bio-Eth.?

As of June 3, 2025, Tulasee Bio-Eth's technical trend is mildly bearish, influenced by bearish moving averages and Bollinger Bands, despite some mixed signals from the MACD and KST indicators.

As of 3 June 2025, the technical trend for Tulasee Bio-Eth has changed from does not qualify to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating mixed signals. The Bollinger Bands are mildly bearish on both the weekly and monthly time frames, and the daily moving averages also reflect a mildly bearish stance. The KST shows a mildly bullish trend weekly but is bearish monthly. Overall, the lack of clear trends in the Dow Theory and OBV further supports a neutral stance in those areas. The current technical stance is mildly bearish, driven primarily by the bearish indicators in the moving averages and Bollinger Bands.

When is the next results date for Tulasee Bio-Eth.?

Tulasee Bio-Eth. will announce its results on 30 July 2025.

Tulasee Bio-Eth. will declare its results on 30 July 2025.

Who are the top shareholders of the Tulasee Bio-Eth.?

The top shareholder of Tulasee Bio-Eth is Ranjana Lalitkumar Nagpal, with an 18.5% stake, while individual investors own 41.94%. There are no institutional holdings or pledged promoter shares.

The top shareholders of Tulasee Bio-Eth include Ranjana Lalitkumar Nagpal, who holds the highest promoter stake at 18.5%. Additionally, individual investors collectively own 41.94% of the company. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

Are Tulasee Bio-Eth. latest results good or bad?

Tulasee Bio-Ethanol's latest results are concerning, showing a 50% drop in net profit and stagnant net sales growth, leading to a 'Strong Sell' rating from analysts. While the company is optimistic about future improvements, investors should be cautious given the current challenges.

Tulasee Bio-Ethanol's latest financial results indicate a challenging quarter. The company's performance has been flat, with a significant decline in its financial score, dropping from 4 to 0. This suggests that the company is facing difficulties, particularly in terms of profitability, as evidenced by a 50% decrease in standalone net profit compared to the same quarter last year.<BR><BR>Moreover, the net sales growth remains stagnant at 0%, which reflects a lack of progress in revenue generation. The overall sentiment from MarketsMOJO rates the stock as a 'Strong Sell,' indicating that analysts have a negative outlook on the company's current situation.<BR><BR>Despite these setbacks, Tulasee Bio-Ethanol is optimistic about its future and is actively working on strategies to improve its financial performance. However, investors should approach with caution, considering the current challenges and the unfavorable rating from analysts.

How has been the historical performance of Tulasee Bio-Eth.?

Tulasee Bio-Eth. has reported zero net sales and operating income from Mar'19 to Mar'25, with negative operating profit and increasing total liabilities and debt. The company's financial health has declined, reflected in worsening reserves and stagnant cash flow.

Answer:<BR>The historical performance of Tulasee Bio-Eth. shows consistent figures over the years, with no net sales or other operating income reported from Mar'19 to Mar'25. Total operating income has remained at zero for the same period, and all major expense categories, including raw material costs, employee costs, and manufacturing expenses, have also consistently reported zero. The only expense that has fluctuated slightly is "Other Expenses," which decreased from 0.57 Cr in Mar'21 to 0.13 Cr in Mar'25. Consequently, the operating profit (PBDIT) has been negative, with a loss of -0.13 Cr reported from Mar'23 to Mar'25, following a profit of 0.48 Cr in Mar'21 and Mar'20. Profit before tax and profit after tax have mirrored this trend, showing losses of -0.13 Cr in the last three years. The company's equity capital has remained stable at 5.84 Cr, while reserves have been negative, decreasing from -4.61 Cr in Mar'21 to -5.14 Cr in Mar'25. The total liabilities have increased slightly from 8.18 Cr in Mar'20 to 8.22 Cr in Mar'25, with total debt rising from 6.66 Cr to 7.38 Cr during the same period. Cash flow statements indicate no cash inflow or outflow across the years, reflecting a stagnant financial position.<BR><BR>Breakdown:<BR>Tulasee Bio-Eth. has not generated any revenue or operating income from Mar'19 to Mar'25, with total operating income consistently at zero. The company has incurred minimal expenses, primarily in "Other Expenses," which have decreased over the years. Operating profit has been negative since Mar'22, with a loss of -0.13 Cr in the last three years, following a profit in the previous two years. The company's equity capital has remained unchanged, while reserves have worsened, indicating a decline in financial health. Total liabilities have seen a slight increase, with total debt rising steadily, reflecting a growing financial burden. The cash flow statements show no activity, highlighting a lack of operational movement or financial transactions during this period.

How has been the historical performance of Tulasee Bio-Eth.?

Tulasee Bio-Eth. has reported zero net sales and operating income from March 2019 to March 2025, with total expenditures decreasing slightly but consistently negative operating profits and profit after tax at -0.13 Cr for the last three years. The company's financial position remains stagnant, with total liabilities and assets showing minimal changes.

Answer:<BR>Tulasee Bio-Eth. has shown a consistent pattern of zero net sales and other operating income over the past several years, indicating no revenue generation from its operations from March 2019 to March 2025. The total operating income has remained at zero throughout this period. The company's total expenditure, excluding depreciation, has been minimal, with the highest recorded at 0.57 Cr in March 2021, which has since decreased to 0.13 Cr by March 2025. Operating profit (PBDIT) has consistently been negative, with losses recorded at -0.13 Cr in the last three years, following a profit of 0.48 Cr in March 2021. The profit after tax has also remained negative at -0.13 Cr for the last three years, reflecting ongoing financial challenges.<BR><BR>Breakdown:<BR>Tulasee Bio-Eth. has not generated any net sales or other operating income from March 2019 to March 2025, maintaining a total operating income of zero. The total expenditure has shown a slight decline from 0.57 Cr in March 2021 to 0.13 Cr in March 2025. Despite this reduction in expenditure, the company has continued to report negative operating profits, with losses of -0.13 Cr in the last three years, down from a profit of 0.48 Cr in March 2021. The profit after tax has mirrored this trend, remaining at -0.13 Cr since March 2023. The company's total liabilities have increased slightly from 8.18 Cr in March 2020 to 8.22 Cr in March 2025, while total assets have also seen a minor increase, indicating a stagnant financial position with no significant growth or recovery in profitability.

Should I buy, sell or hold Tulasee Bio-Eth.?

Which are the latest news on Tulasee Bio-Eth.?

Why is Tulasee Bio-Eth. falling/rising?

As of 04-Dec, Tulasee Bio-Ethanol Ltd's stock price is at 50.39, reflecting a 5.0% decline. The stock has underperformed significantly over the past week and month, with a notable drop in investor participation contributing to its current challenges.

As of 04-Dec, Tulasee Bio-Ethanol Ltd's stock price is falling, currently at 50.39, which reflects a decrease of 2.65 or 5.0%. This decline is evident in the stock's performance today, where it underperformed its sector by 4.79% and opened with a loss of 5%. Additionally, the stock touched an intraday low of Rs 50.39, indicating a lack of upward momentum.<BR><BR>Over the past week, the stock has experienced a significant drop of 14.24%, contrasting sharply with the Sensex, which only fell by 0.53%. The one-month performance shows a decline of 26.39% for Tulasee Bio-Ethanol Ltd, while the Sensex gained 2.16%. This trend suggests that the stock is not only underperforming relative to the broader market but also facing substantial selling pressure.<BR><BR>Investor participation appears to be declining, as evidenced by a 37.5% drop in delivery volume on December 2 compared to the five-day average. This reduction in trading activity may contribute to the stock's price decline, as lower participation can lead to increased volatility and downward pressure on prices.<BR><BR>Despite a strong year-to-date performance of 183.09%, the recent trends indicate that the stock is currently facing challenges that are leading to its falling price.